[Management of malignant ascites by intraperitoneal injection of OK-432. Possible mechanism of the reduction of original tumor mass volume].
We studied the effect of intraperitoneal injection of OK-432 on the growth of original tumor mass in patients with malignant ascites and a possible mechanism of reduction of tumor volume. Sixteen patients with valuable original tumor mass and a large amount of ascites caused by gastro-intestinal cancer were studied. Tumor cells were separated from ascitic fluids and cultured in vitro before the study. Lymphocytes were collected from the fluids at varying intervals after intraperitoneal injection of OK-432 and cultured 24 hours in vitro. Effect of the culture supernatant on ascites-derived autologous tumor cell growth was examined in vitro using microplate assay. The results were as follows. 1) Reduction of tumor mass more than four weeks was found in 4 of 16 cases. 2) Before OK-432 injection, the culture supernatant from ascites-derived lymphocytes did not inhibit autotumor cell growth in vitro. But, the supernatant from lymphocytes which were collected from the ascites after OK-432 injection markedly inhibited tumor growth in all of 4 tumor mass reduction cases. In 12 non-reduction cases the supernatant slightly inhibited tumor growth only in 2 cases. 3) A similar growth inhibitory factor was detected in the mixed culture-supernatant of peripheral blood lymphocytes and OK-432 in vitro. 4) Preliminary studies indicated that the tumor growth inhibitory factor might be different from tumor necrosis factor and interferons. These results indicate that ascites-derived lymphocytes-producing factor may play an important role in reduction of tumor mass volume in patients with cancerous ascites.
Katano
M
M
Department of Surgery, Saga Medical School, Japan.
Mizoguchi
T
T
Yamamoto
H
H
Hisatsugu
T
T
Torisu
M
M
D000230:Adenocarcinoma / Q000150:complications / Q000628:therapy*; D000328:Adult; D000368:Aged; D001688:Biological Products / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000150:complications / Q000628:therapy*; D006801:Humans; D007274:Injections, Intraperitoneal; D008297:Male; D008875:Middle Aged; D010538:Peritonitis / Q000209:etiology / Q000628:therapy*; D010844:Picibanil / Q000008:administration & dosage / Q000627:therapeutic use*
D001688:Biological Products; D010844:Picibanil